Time duration and health care resource use during cancer diagnoses in the United States: A large claims database analysis

Gitlin, Matthew; McGarvey, November; Shivaprakash, Namrata; Cong, Ze

doi:10.18553/jmcp.2023.29.6.659

Cited by 2 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Instead, current UK guideline recommendations (issued in 2015) chiefly relate to symptoms of specific cancer sites [ 6 ], meaning that, as we show, the broader cancer site case-mix of different symptoms (particularly vague symptoms) is not appreciated. There is no equivalent single body of guidelines for presenting symptoms in the US setting, although evidence indicates that diagnostic delays in symptomatic patients subsequently diagnosed with cancer are comparable to those seen in Europe, and that the predictive values of different symptoms among presenters are also similar [ 20 , 21 ]. Recent evidence demonstrates that the predictive values of three common vague symptoms, i.e.…”

Section: Discussionmentioning

confidence: 99%

The presenting symptom signatures of incident cancer: evidence from the English 2018 National Cancer Diagnosis Audit

Zakkak,

Barclay,

Swann

et al. 2023

Br J Cancer

View full text Add to dashboard Cite

Background Understanding relationships between presenting symptoms and subsequently diagnosed cancers can inform symptom awareness campaigns and investigation strategies. Methods We used English National Cancer Diagnosis Audit 2018 data for 55,122 newly diagnosed patients, and examined the relative frequency of presenting symptoms by cancer site, and of cancer sites by presenting symptom. Results Among 38 cancer sites (16 cancer groups), three classes were apparent: cancers with a dominant single presenting symptom (e.g. melanoma); cancers with diverse presenting symptoms (e.g. pancreatic); and cancers that are often asymptomatically detected (e.g. chronic lymphocytic leukaemia). Among 83 symptoms (13 symptom groups), two classes were apparent: symptoms chiefly relating to cancers of the same body system (e.g. certain respiratory symptoms mostly relating to respiratory cancers); and symptoms with a diverse cancer site case-mix (e.g. fatigue). The cancer site case-mix of certain symptoms varied by sex. Conclusion We detailed associations between presenting symptoms and cancer sites in a large, representative population-based sample of cancer patients. The findings can guide choice of symptoms for inclusion in awareness campaigns, and diagnostic investigation strategies post-presentation when cancer is suspected. They can inform the updating of clinical practice recommendations for specialist referral encompassing a broader range of cancer sites per symptom.

show abstract

Section: Discussionmentioning

confidence: 99%

The presenting symptom signatures of incident cancer: evidence from the English 2018 National Cancer Diagnosis Audit

Zakkak,

Barclay,

Swann

et al. 2023

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…[ 7 – 9 ] MM is associated with significant morbidity and mortality, and it poses a substantial burden on patients and healthcare systems worldwide. [ 10 , 11 ]…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma: A meta-analysis of randomized controlled trials

Huang,

Jin,

Liang

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: Daratumumab as a monoclonal antibody has shown promising results in the treatment of relapsed/refractory multiple myeloma (RRMM). However, the efficacy and safety of daratumumab-based regimens compared to control regimens have not been fully established. Methods: The search was conducted using electronic databases (PubMed, Web of Science, Embase, and Cochrane Central Register of Controlled Trials databases) up to December 2022. We conducted a meta-analysis of randomized controlled trials that evaluated the efficacy and safety of daratumumab in the treatment of RRMM. Data were extracted from eligible studies and were presented as hazard ratio or risk ratio (RR) with 95% confidence interval (CI). Results: A total of 5 randomized controlled trials comprising 2003 patients were included in this meta-analysis. The results showed that daratumumab-based regimens significantly improved progression-free survival compared to control regimens (hazard ratio = 0.44, 95% CI 0.32–0.60, P < .00001). Additionally, daratumumab-based regimens significantly improved overall response rate compared to control regimens (RR = 1.25, 95% CI 1.16–1.36, P < .00001). the rate of minimal residual disease was also significantly higher in the daratumumab-based regimens (RR = 6.10, 95% CI 4.09–9.11, P < .00001). However, there was an increased risk of pneumonia, upper respiratory tract infections, and diarrhea in the daratumumab-based regimens. Conclusion: Our results suggest that daratumumab-based regimens are effective in the treatment of RRMM, improving progression-free survival, minimal residual disease, and overall response rate. However, there is an increased risk of pneumonia, upper respiratory tract infections, and diarrhea. Further studies are needed to determine the long-term safety and efficacy of daratumumab in the treatment of multiple myeloma.

show abstract

Time duration and health care resource use during cancer diagnoses in the United States: A large claims database analysis

Cited by 2 publications

References 42 publications

The presenting symptom signatures of incident cancer: evidence from the English 2018 National Cancer Diagnosis Audit

The presenting symptom signatures of incident cancer: evidence from the English 2018 National Cancer Diagnosis Audit

Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma: A meta-analysis of randomized controlled trials

Contact Info

Product

Resources

About